Feb 23 2010
“We are very fortunate to have a strong and productive partnership
with Allergan, which allows both companies to take advantage of
opportunities to shorten development timelines and rapidly move to
create new shared products and value”
ExonHit Therapeutics (Paris:ALEHT) today announced the inclusion of
proprietary lead compounds, which were derived from one of its internal
medicinal chemistry programs, into its productive and long-running
strategic collaboration with Allergan.
"We are very fortunate to have a strong and productive partnership
with Allergan, which allows both companies to take advantage of
opportunities to shorten development timelines and rapidly move to
create new shared products and value," stated Loïc Maurel M.D.,
President of ExonHit Therapeutics' Management Board.
ExonHit will continue to lead the medicinal chemistry effort related to
this target. The compounds are active against a new enzyme target
potentially useful for therapeutic development in ophthalmology and
neurodegenerative indications. Milestone and royalty terms of the
existing collaboration agreement will apply to these compounds and the
products derived from them.
Revvity Signals Software unveils Signals Clinical solution to accelerate critical clinical trial insights and data-driven decisions